CBIO Q3 2025 Earnings — Crescent Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

CBIOCrescent Biopharma, Inc.

$345M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$31M

Gross Profit

$29M94.7% margin

Operating Income

-$26M-84.7% margin

Net Income

-$25M-80.5% margin

EPS (Diluted)

$0.03

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$138M

Total Liabilities

$22M

Stockholders' Equity

$117M

Cash & Equivalents

$133M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$31M	$0	—
Gross Profit	$29M	-$8,130	+356016.4%
Operating Income	-$26M	-$11M	-130.4%
Net Income	-$25M	-$10M	-150.5%

Revenue Segments

Product

$31M100%